B. Riley Comments on Altimmune, Inc.’s Q1 2024 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALTFree Report) – Research analysts at B. Riley issued their Q1 2024 EPS estimates for shares of Altimmune in a note issued to investors on Thursday, March 28th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of ($0.30) for the quarter. B. Riley currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.37) per share. B. Riley also issued estimates for Altimmune’s Q2 2024 earnings at ($0.30) EPS.

Separately, The Goldman Sachs Group initiated coverage on Altimmune in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 target price on the stock.

Read Our Latest Analysis on Altimmune

Altimmune Trading Up 14.5 %

NASDAQ ALT opened at $10.18 on Friday. Altimmune has a 1-year low of $2.09 and a 1-year high of $14.84. The firm’s fifty day simple moving average is $9.92 and its 200-day simple moving average is $6.80. The company has a market capitalization of $546.97 million, a PE ratio of -6.17 and a beta of 0.08.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Altimmune by 162.9% during the second quarter. BlackRock Inc. now owns 3,664,274 shares of the company’s stock valued at $12,935,000 after purchasing an additional 2,270,219 shares during the last quarter. Vanguard Group Inc. grew its stake in Altimmune by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 3,571,972 shares of the company’s stock valued at $40,185,000 after buying an additional 227,677 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in Altimmune by 5.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,458,949 shares of the company’s stock worth $12,210,000 after acquiring an additional 190,888 shares during the period. State Street Corp lifted its position in Altimmune by 2,407.5% during the 3rd quarter. State Street Corp now owns 3,398,856 shares of the company’s stock worth $43,403,000 after acquiring an additional 3,263,310 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Altimmune by 28.9% during the 2nd quarter. Marshall Wace LLP now owns 2,059,290 shares of the company’s stock worth $7,269,000 after acquiring an additional 462,160 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

(Get Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.

See Also

Earnings History and Estimates for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.